ASP7517

BIOLOGICAL2 trials

Sponsors

Astellas Pharma Global Development, Inc.

Conditions

Acute Myeloid Leukemia (AML)Advanced CancerAdvanced MalignanciesMyelodysplastic Syndrome

Phase 1

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

CompletedNCT04079296

Astellas Pharma Global Development, Inc.Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome

Start: 2019-09-19End: 2023-04-21Updated: 2024-11-26

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

CompletedNCT04837196

Astellas Pharma Global Development, Inc.Advanced Cancer, Advanced Malignancies

Start: 2021-11-11End: 2024-06-21Updated: 2025-08-08